APR 2013

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/119916

Contents of this Issue


Page 39 of 82

April 2013 86% of dry eye patients have signs of Meibomian Gland Dysfunction. 1 Restasis, and these improve over time so that by three months after starting Restasis, the burning and stinging almost always goes away," Dr. Donnenfeld said. Dr. Mah also offers patients some tips to help minimize the burning sensation. "I usually tell patients to put the Restasis in the refrigerator," Dr. Mah said. "Typically that cold drop stings less." If that doesn't help, he recommends using artificial tears or a palliative lubricating eye drop first, waiting five minutes and then putting the Restasis in afterward. To help patients respond more quickly to Restasis as well as minimize burning, Dr. Donnenfeld adds a topical corticosteroid to the treatment. "I've been very impressed by a new mediation, a loteprednol gel that has a vehicle that stays in the tear film longer," he said. He recommends using this twice a day for one month in conjunction with Restasis therapy. "This makes patients respond more quickly and it eliminates the burning in a significant way," Dr. Donnenfeld said. Restasis is not something that should be reserved just for the worst dry eye cases, Dr. Mah said. He has found success using this on patients earlier on in therapy when their symptoms first arise and they first begin to use artificial tears. Ironically, keeping track of artificial tear amounts can help patients to monitor their progress on Restasis. For example, Dr. Mah tells patients to continue using their artificial tears at the same dosages that they have been prior to starting Restasis and to take note if they begin using less over time. He finds it helpful to follow up with patients on this, especially in cases where patients are questioning their progress on the medication. "Many times patients will say, 'I do think that I'm using less artificial tears than before,'" he said. "That's an indication that their dry eyes are improving." Of course even with the best support system in place to help patients, Restasis may not work for everyone. Dr. Donnenfeld pointed out that some may not actually have aqueous deficiency dry eye. "A lot of patients who come in with 'aqueous deficiency' dry eye are given Restasis when in actuality they have meibomian gland dysfunction," he said. "The lack of response to Restasis is related to the fact that we were treating the wrong disease and that all dry eye is not the same," he concluded. EW Treat the cause Editors' note: Dr. Donnenfeld has financial interests with Allergan and Bausch + Lomb (Rochester, N.Y.). Dr. Mah has financial interests with Allergan. Contact information Donnenfeld: 516-446-3525, ericdonnenfeld@gmail.com Mah: 858-554-9093, mah.francis@scrippshealth.org Send us your favorite APP! Have a favorite app that helps you with business or personal activities? Email stacy@eyeworld.org with the app name and how it helped you. Apps selected will be published in Ophthalmology Business and their submitters will receive a $50 iTunes card. You may be selected for a brief interview. Visit tearscience.com for complete product and safety information. 1 Lemp MA, et al. Distribution of aqueous deficient and evaporative dry eye in a clinic-based population. Cornea. 2012 May;31(5):472-8 LipiFlow is a registered trademark of TearScience, Inc. Copyright © 2013 TearScience, Inc. All rights reserved. 13-ADV-08 RevB

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - APR 2013